Why the study?
Does bepridil improve sinus rhythm conversion and what is its safety profile in patients with persistent atrial fibrillation?
Does bepridil improve sinus rhythm conversion and what is its safety profile in patients with persistent atrial fibrillation?
In a post-marketing surveillance of patients with persistent atrial fibrillation, bepridil showed a 59.6% sinus rhythm conversion rate, with QT prolongation being the most common adverse event (11.5%).
Answers are grounded in this paper and cite their sources.
Bepridil was associated with sinus conversion alongside QT prolongation risk in persistent AF; leaves open its comparative role versus alternatives.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ugumori et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: